Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma

Abstract

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for

Adjuvant therapy for renal cell carcinoma

“…The EVEREST randomized phase 3 trial is evaluating everolimus in the post radical or partial nephrectomy setting, and it is estimated to complete enrolment by the end of 2021. The primary endpoint is RFS, and a key secondary endpoint is OS [30] .…”